Work

A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Year: 2012

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v120.21.1643.1643

Authors: Kristie A. Blum, Beth Christian, Joseph M. Flynn, Samantha M. Jaglowski, Jeffrey Alan Jones, Kami Maddocks, John C. Byrd

Institutions: The Ohio State University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2582857650

FWCI: 3.033

Cites:

Cited by: 28

Related to: 10